650 related articles for article (PubMed ID: 33790428)
1. Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm.
Nakamura Y; Kawazoe A; Lordick F; Janjigian YY; Shitara K
Nat Rev Clin Oncol; 2021 Aug; 18(8):473-487. PubMed ID: 33790428
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1.
Fashoyin-Aje L; Donoghue M; Chen H; He K; Veeraraghavan J; Goldberg KB; Keegan P; McKee AE; Pazdur R
Oncologist; 2019 Jan; 24(1):103-109. PubMed ID: 30120163
[TBL] [Abstract][Full Text] [Related]
3. Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies.
Cappetta A; Lonardi S; Pastorelli D; Bergamo F; Lombardi G; Zagonel V
Crit Rev Oncol Hematol; 2012 Jan; 81(1):38-48. PubMed ID: 21256046
[TBL] [Abstract][Full Text] [Related]
4. What Therapeutic Biomarkers in Gastro-Esophageal Junction and Gastric Cancer Should a Pathologist Know About?
Kumarasinghe MP; Houghton D; Allanson BM; Price TJ
Surg Pathol Clin; 2023 Dec; 16(4):659-672. PubMed ID: 37863558
[TBL] [Abstract][Full Text] [Related]
5. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
[TBL] [Abstract][Full Text] [Related]
6. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Tabernero J; Hoff PM; Shen L; Ohtsu A; Shah MA; Cheng K; Song C; Wu H; Eng-Wong J; Kim K; Kang YK
Lancet Oncol; 2018 Oct; 19(10):1372-1384. PubMed ID: 30217672
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological features of PD-L1 protein expression, EBV positivity, and MSI status in patients with advanced gastric and esophagogastric junction adenocarcinoma in Japan.
Yoshida T; Ogura G; Tanabe M; Hayashi T; Ohbayashi C; Azuma M; Kunisaki C; Akazawa Y; Ozawa S; Matsumoto S; Suzuki T; Mitoro A; Fukunaga T; Shimizu A; Fujimoto G; Yao T
Cancer Biol Ther; 2022 Dec; 23(1):191-200. PubMed ID: 35220884
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Shitara K; Özgüroğlu M; Bang YJ; Di Bartolomeo M; Mandalà M; Ryu MH; Fornaro L; Olesiński T; Caglevic C; Chung HC; Muro K; Goekkurt E; Mansoor W; McDermott RS; Shacham-Shmueli E; Chen X; Mayo C; Kang SP; Ohtsu A; Fuchs CS;
Lancet; 2018 Jul; 392(10142):123-133. PubMed ID: 29880231
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
Maron SB; Chase LM; Lomnicki S; Kochanny S; Moore KL; Joshi SS; Landron S; Johnson J; Kiedrowski LA; Nagy RJ; Lanman RB; Kim ST; Lee J; Catenacci DVT
Clin Cancer Res; 2019 Dec; 25(23):7098-7112. PubMed ID: 31427281
[TBL] [Abstract][Full Text] [Related]
10. Survey of Her2-neu Expression and its Correlation with Histology of Gastric Carcinoma and Gastroesophageal Junction Adenocarcinoma.
Madani SH; Rahmati A; Sadeghi E; Khazaei S; Sadeghi M; Payandeh M; Amirifard N
Asian Pac J Cancer Prev; 2015; 16(17):7755-8. PubMed ID: 26625793
[TBL] [Abstract][Full Text] [Related]
11. Clonality analysis of synchronous gastro-oesophageal junction carcinoma and distal gastric cancer by whole-exome sequencing.
Xing X; Jia S; Wu J; Feng Q; Dong B; Li B; Jia Y; Shan F; Li Y; Zhang Y; Hu Y; Wang X; Liu X; Yu W; Zhang L; Bu Z; Wu A; Li Z; Ji J
J Pathol; 2017 Oct; 243(2):165-175. PubMed ID: 28671728
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
[TBL] [Abstract][Full Text] [Related]
13. Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer.
Wagner AD; Lordick F; Grabsch HI; Terashima M; Terada M; Yoshikawa T; Boku N; Kataoka K; Smyth EC; Mauer M; Haustermans K; Moehler MH
Eur J Cancer; 2020 Jan; 124():67-76. PubMed ID: 31759294
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.
Joshi SS; Maron SB; Catenacci DV
Future Oncol; 2018 Feb; 14(5):417-430. PubMed ID: 29094609
[TBL] [Abstract][Full Text] [Related]
15. Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies.
Kim S; Barzi A; Rajdev L
Semin Oncol; 2018 Jun; 45(3):133-150. PubMed ID: 30262395
[TBL] [Abstract][Full Text] [Related]
16. Acquired microsatellite instability status and loss of HER2 positivity during treatment of gastro-esophageal junction adenocarcinoma.
Alexis LG; Dano H; Dekairelle AF; Van Marcke C; Van den Eynde M
Dig Liver Dis; 2023 Mar; 55(3):426-428. PubMed ID: 36577596
[No Abstract] [Full Text] [Related]
17. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial.
Rivera F; Izquierdo-Manuel M; García-Alfonso P; Martínez de Castro E; Gallego J; Limón ML; Alsina M; López L; Galán M; Falcó E; Manzano JL; González E; Muñoz-Unceta N; López C; Aranda E; Fernández E; Jorge M; Jiménez-Fonseca P
Eur J Cancer; 2021 Mar; 145():158-167. PubMed ID: 33485079
[TBL] [Abstract][Full Text] [Related]
18. Adenocarcinoma of the GEJ: gastric or oesophageal cancer?
Rüschoff J
Recent Results Cancer Res; 2012; 196():107-13. PubMed ID: 23129369
[TBL] [Abstract][Full Text] [Related]
19. Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ).
Bang YJ; Golan T; Dahan L; Fu S; Moreno V; Park K; Geva R; De Braud F; Wainberg ZA; Reck M; Goff L; Laing N; Mi G; Oliveira JM; Wasserstrom H; Lin CC
Eur J Cancer; 2020 Sep; 137():272-284. PubMed ID: 32827847
[TBL] [Abstract][Full Text] [Related]
20. HER2 testing of gastro-oesophageal adenocarcinoma: a commentary and guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Committee.
Wong NACS; Amary F; Butler R; Byers R; Gonzalez D; Haynes HR; Ilyas M; Salto-Tellez M; Taniere P
J Clin Pathol; 2018 May; 71(5):388-394. PubMed ID: 29439009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]